Drugs Information:
Duvelisib
Basic Information
|
|
||
| ID | DDInter612 | |
| Drug Type | small molecule | |
| Molecular Formula | C22H17ClN6O | |
| Molecular Weight | 416.870 | |
| CAS Number | 1201438-56-3 | |
| Description | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] | |
| ATC Classification | L01EM04 | |
| IUPAC Name | 8-chloro-2-phenyl-3-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-1,2-dihydroisoquinolin-1-one | |
| InChI | SJVQHLPISAIATJ-ZDUSSCGKSA-N | |
| Canonical SMILES | C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 | |
| Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL ZINC | |
Interactions with
Duvelisib
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|